Last updated: February 23, 2026
What is the drug?
NDC 00049-4910 corresponds to Galcanezumab, marketed as Emgality. It is a monoclonal antibody developed by Eli Lilly for the preventive treatment of migraine in adults. It is approved as a once-monthly injection.
Market Overview
Market size
The migraine prevention segment targets a broad patient population, with approximately 39 million adults in the U.S. suffering from migraines, of whom an estimated 20 million qualify for preventive therapy. The global migraine therapeutics market was valued at $3.2 billion in 2021 and is projected to reach $5.4 billion by 2028, with a compound annual growth rate (CAGR) of 7.7%.
Competition
Key competitors include:
- Erenumab (Aimovig) by Amgen.
- Fremanezumab (Ajovy) by Teva.
- Eptinezumab (Vyepti) by Lundbeck/Pfizer.
All are calcitonin gene-related peptide (CGRP) inhibitors. The landscape is competitive, with multiple drugs targeting the same pathway.
Approval and indications
NDC 00049-4910 (Galcanezumab) gained FDA approval in September 2018 for:
- Preventive treatment of migraine in adults.
- Reduction of monthly migraine days.
It received broad approval in EU markets in 2019.
Pricing Insights
Launch price
- The initial list price for Emgality was approximately $575 per injection (monthly).
- Annual cost estimated at $6,900 based on monthly dosing.
Cost comparison
| Drug |
Dosing Schedule |
Average Annual Cost |
Marketed Price (USD) |
| Emgality (NDC 00049-4910) |
Monthly injection |
$6,900 |
$575/injection |
| Aimovig |
Monthly injection |
$6,800 |
Similar to Emgality |
| Ajovy |
Monthly or quarterly |
$6,600–$8,200 |
Variable, per dose |
| Vyepti |
Quarterly infusions |
$10,000 |
Higher, due to administration |
Pricing trends
Prices for CGRP inhibitors remain relatively stable, with minor adjustments driven by pharmacy negotiations and insurer contracts. Price reduction strategies, such as value-based agreements, are emerging but limited.
Market Dynamics
Adoption
- Physicians are increasingly prescribing these therapies due to their efficacy.
- Insurance coverage is broad but involves prior authorization.
- The high cost influences patient access and adherence.
Patents and exclusivity
- Original patents for Galcanezumab held until 2030.
- Patent challenges and biosimilar entry could impact future pricing.
Regulatory landscape
- Approval in multiple regions broadens accessible markets.
- Ongoing patents prevent biosimilars from entering the market until at least 2030.
Price Projections
Short-term (2023–2025)
- List prices are expected to remain stable, with slight reductions (~2-3%) from market negotiations.
- Price discounts may increase via manufacturer-led rebate programs and value-based contracts.
Mid-term (2026–2030)
- Market entry of biosimilars or biosimilar-approved products could reduce prices by 20–30%.
- Manufacturers may implement tiered pricing to maintain market share.
Long-term (post-2030)
- Patent expiration likely leads to biosimilar competition.
- Prices could decline by 50% or more, aligning with similar biologics.
Key Trends Influencing Pricing
- Expansion of indications, such as for cluster headaches and other pain disorders.
- Transition towards value-based reimbursement models.
- Prescriber and insurer focus on cost-effectiveness data.
Summary
Galcanezumab (NDC 00049-4910) remains a premium-priced CGRP therapy with stable pricing through 2025. Potential biosimilar entry around 2030 may disrupt pricing, leading to substantial reductions. Current market growth is driven by expanding migraine prevalence and increasing awareness.
Key Takeaways
- The drug’s annual list price is approximately $6,900.
- Competition maintains similar pricing, with slight variations.
- Patent protections delay biosimilar competition until at least 2030.
- Market growth hinges on insurance coverage and physician adoption.
- Pricing reductions are expected post-patent expiry, potentially halving the price.
FAQs
1. When will biosimilars for galcanezumab likely enter the market?
Expected around 2030, following patent expiration and biosimilar approval processes.
2. How does insurance coverage affect the final patient cost?
Rebates, prior authorizations, and co-pay assistance lower out-of-pocket expenses, but patient costs can vary significantly.
3. Are there upcoming formulations or delivery methods?
Currently, no new delivery methods have been approved. Subcutaneous injections remain standard.
4. Can the price of galcanezumab be reduced through patient assistance programs?
Yes, Eli Lilly offers patient assistance programs that can substantially lower out-of-pocket costs.
5. What impact will new CGRP inhibitors have on the market?
They will intensify competition, potentially leading to price competition and increased market penetration.
References
[1] IQVIA. (2022). Global migraine therapeutic market report.
[2] FDA. (2018). Emgality (Galcanezumab) approval letter.
[3] Eli Lilly. (2021). Emgality pricing and reimbursement updates.
[4] EvaluatePharma. (2022). Biologic drug pricing and patent expiry forecasts.
[5] MarketWatch. (2022). CGRP inhibitor market growth projections.
